[go: up one dir, main page]

MA34383B1 - Analogues de glucagon - Google Patents

Analogues de glucagon

Info

Publication number
MA34383B1
MA34383B1 MA35571A MA35571A MA34383B1 MA 34383 B1 MA34383 B1 MA 34383B1 MA 35571 A MA35571 A MA 35571A MA 35571 A MA35571 A MA 35571A MA 34383 B1 MA34383 B1 MA 34383B1
Authority
MA
Morocco
Prior art keywords
methods
relates
glucagon
compounds
glucagon analogues
Prior art date
Application number
MA35571A
Other languages
English (en)
Inventor
Ditte Riber
Eddi Meier
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44630046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34383(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MA34383B1 publication Critical patent/MA34383B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des substances et des procédés pour favoriser la perte de poids ou prévenir le gain de poids et pour traiter le diabète ou des troubles associés. En particulier, l'invention concerne de nouveaux composés peptidiques d'analogues de glucagon efficaces dans de tels procédés. Les composés peuvent procurer leur effet en ayant, par exemple, une sélectivité accrue pour le récepteur GLP-1 comparée au glucagon humain.
MA35571A 2010-06-24 2011-06-24 Analogues de glucagon MA34383B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201000558 2010-06-24
US35861410P 2010-06-25 2010-06-25
PCT/DK2011/000072 WO2011160633A1 (fr) 2010-06-24 2011-06-24 Analogues de glucagon

Publications (1)

Publication Number Publication Date
MA34383B1 true MA34383B1 (fr) 2013-07-03

Family

ID=44630046

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35571A MA34383B1 (fr) 2010-06-24 2011-06-24 Analogues de glucagon

Country Status (21)

Country Link
US (2) US9169310B2 (fr)
EP (1) EP2585482B1 (fr)
JP (1) JP6023048B2 (fr)
KR (1) KR20130086343A (fr)
CN (1) CN103068841A (fr)
AP (1) AP2013006671A0 (fr)
AU (1) AU2011269430A1 (fr)
BR (1) BR112012033225A2 (fr)
CA (1) CA2802897A1 (fr)
CL (1) CL2012003641A1 (fr)
CO (1) CO6660483A2 (fr)
EA (1) EA201291234A1 (fr)
EC (1) ECSP12012357A (fr)
MA (1) MA34383B1 (fr)
MX (1) MX2012014961A (fr)
NZ (1) NZ604208A (fr)
PE (1) PE20130338A1 (fr)
PH (1) PH12012502472A1 (fr)
SG (1) SG186764A1 (fr)
TN (1) TN2012000560A1 (fr)
WO (1) WO2011160633A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104605C2 (uk) 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
CA2747155A1 (fr) 2008-12-15 2010-06-24 Zealand Pharma A/S Analogues du glucagon
CN102292348B (zh) 2008-12-15 2015-07-08 西兰制药公司 胰高血糖素类似物
EA022816B1 (ru) 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
EP2585462B1 (fr) 2010-06-24 2020-02-26 Takeda Pharmaceutical Company Limited Composés hétérocycliques condensés comme inhibiteurs de phosphodiestérases (pdes)
JP6023048B2 (ja) 2010-06-24 2016-11-09 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN104093735B (zh) * 2011-09-23 2018-07-06 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
EA028665B1 (ru) 2012-05-03 2017-12-29 Зилэнд Фарма А/С Соединения - двойные агонисты gip-glp-1 и способы
NZ704043A (en) * 2012-07-23 2017-07-28 Zealand Pharma As Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
BR112015025464A2 (pt) 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
HRP20181505T1 (hr) 2013-10-17 2018-11-02 Zealand Pharma A/S Acilirani analozi glukagona
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
MX369770B (es) 2013-11-06 2019-11-21 Zealand Pharma As Compuestos agonistas triples de glucagón-glp-1-gip.
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
WO2015193378A1 (fr) * 2014-06-18 2015-12-23 Novo Nordisk A/S Nouveaux agonistes des récepteurs au glp-1 à activité d'efflux de cholestérol
EP3204408B1 (fr) * 2014-10-10 2020-05-06 Novo Nordisk A/S Co-agonistes du récepteur glp-1/glucagon à base de glp-1 stable
MX381640B (es) 2014-10-29 2025-03-04 Zealand Pharma As Metodos y compuestos agonistas de gip.
UA121874C2 (uk) 2015-02-17 2020-08-10 Елі Ліллі Енд Компані Порошкова назальна композиція для лікування гіпоглікемії
AR103954A1 (es) 2015-03-18 2017-06-14 Zealand Pharma As Análogos de amilina
WO2016168388A2 (fr) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Thérapies pour l'obésité, le diabète et indications associées
KR20170137198A (ko) * 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
AU2017307033B2 (en) 2016-08-05 2020-11-26 Boehringer Ingelheim International Gmbh Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
JP6563614B1 (ja) * 2016-12-09 2019-08-21 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
CN116854804A (zh) * 2017-08-16 2023-10-10 东亚St株式会社 酰化胃泌酸调节素肽类似物
CA3087827A1 (fr) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Derives d'oxadiazolopyridine a substitution heterocyclyle utilises en tant qu'inhibiteurs de la ghreline o-acyltransferase (goat)
CN111630055B (zh) 2018-02-02 2023-07-14 勃林格殷格翰国际有限公司 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物
EA202091803A1 (ru) 2018-02-02 2020-12-16 Бёрингер Ингельхайм Интернациональ Гмбх Производные триазолопиримидина для применения в качестве ингибиторов грелин-о-ацилтрансферазы (goat)
KR20200116978A (ko) 2018-02-02 2020-10-13 베링거 인겔하임 인터내셔날 게엠베하 그렐린 o-아실 트랜스퍼라제(goat) 억제제로서의 벤질-치환된, (피리딘-3-일)메틸-치환된 또는 (피리딘-4-일)메틸-치환된 옥사디아졸로피리딘 유도체
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
JP7702969B2 (ja) 2020-05-22 2025-07-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル７－アミノ－５－メチル－［１，２，５］オキサジアゾロ［３，４－ｂ］ピリジンカルボキシレートの連続製造方法
EP4153599B1 (fr) 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Procédé de fabrication de 7-amino-5-méthyl- [1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle
WO2022029231A1 (fr) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Agonistes du récepteur npy2 solubles
WO2023016346A1 (fr) * 2021-08-10 2023-02-16 南京明德新药研发有限公司 Composé polypeptidique contenant un pont lactame
CN115490760B (zh) * 2022-07-04 2023-04-14 北京惠之衡生物科技有限公司 一种glp-1受体和gcg受体共激动多肽衍生物
WO2025219590A1 (fr) 2024-04-19 2025-10-23 Actimed Therapeutics Ltd Bêta-bloquants pour préserver la masse musculaire, la densité osseuse et la fonction cardiaque lors de traitements de perte de poids

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
BRPI9711437B8 (pt) 1996-08-30 2021-05-25 Novo Nordisk As derivados de glp-1
ES2239364T3 (es) 1996-09-09 2005-09-16 Zealand Pharma A/S Sintesis de peptidos en fase solida.
CA2265454A1 (fr) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Promedicaments peptidiques contenant une sequence de liaison alpha-hydroxyacide
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
CA2310097C (fr) 1997-11-14 2014-07-29 Amylin Pharmaceuticals, Inc. Nouveaux composes agonistes de l'exendine
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6903186B1 (en) 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
CZ20013018A3 (cs) 1999-03-17 2002-02-13 Novo Nordisk A/S Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003053460A1 (fr) 2001-12-19 2003-07-03 Eli Lilly And Company Compositions cristallines pour reguler la glycemie
HUP0700126A2 (en) 2001-12-20 2007-06-28 Lilly Co Eli Insulin molecule having protracted time action
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2518776A1 (fr) 2003-04-29 2004-11-11 Eli Lilly And Company Analogues de l'insuline ayant une action prolongee
CN101155828A (zh) * 2005-02-11 2008-04-02 安米林药品公司 Gip类似物和具有可选择性质的杂合多肽
RU2485135C2 (ru) 2005-06-13 2013-06-20 Импиэриэл Инноувейшнс Лимитид Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
US20090202497A1 (en) 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
CN101534846B (zh) 2005-11-07 2014-11-05 印第安纳大学研究及科技有限公司 显示生理学溶解性和稳定性的胰高血糖素类似物
WO2007081824A2 (fr) 2006-01-06 2007-07-19 Case Western Reserve University Protéines résistantes à la fibrillation
US7928058B2 (en) 2006-02-22 2011-04-19 Merck Sharp & Dohme Corp. Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
CA2658276A1 (fr) 2006-07-18 2008-01-24 Sanofi-Aventis Anticorps antagoniste destine au traitement du cancer
EP2074140B8 (fr) 2006-10-04 2015-10-28 Case Western Reserve University Insuline et analogues de l'insuline résistants à la fibrillation
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
EP2025684A1 (fr) 2007-08-15 2009-02-18 Zealand Pharma A/S Analogues du glucagon
US7994122B2 (en) 2007-06-15 2011-08-09 Zealand Pharma A/S Glucagon analogues
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111682A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
WO2009129250A2 (fr) 2008-04-14 2009-10-22 Case Western Reserve University Analogues de l'insuline à prendre au moment des repas de stabilité améliorée
RU2010147076A (ru) 2008-04-22 2012-05-27 Кейз Вестерн Ризев Юнивесити (Us) Аналоги инсулина специфичные к изоформам
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
PA8830501A1 (es) 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
CN102088989B (zh) 2008-06-17 2014-11-26 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
WO2010014946A2 (fr) 2008-07-31 2010-02-04 Case Western Reserve University Insuline stabilisée par de l'halogène
CN102292348B (zh) 2008-12-15 2015-07-08 西兰制药公司 胰高血糖素类似物
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
CA2747155A1 (fr) 2008-12-15 2010-06-24 Zealand Pharma A/S Analogues du glucagon
UA104605C2 (uk) * 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
CA2747490C (fr) 2008-12-19 2017-02-14 Indiana University Research And Technology Corporation Analogues d'insuline
WO2010080609A1 (fr) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Promédicaments insuliniques à base d'amide
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
EA022816B1 (ru) * 2009-07-13 2016-03-31 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
CA2786934A1 (fr) 2010-01-20 2011-07-28 Zealand Pharma A/S Traitement d'etats pathologiques cardiaques
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
JP6023048B2 (ja) 2010-06-24 2016-11-09 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
PH12013501495A1 (en) 2011-01-20 2013-09-16 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
AP2014007797A0 (en) 2011-12-23 2014-07-31 Boehringer Ingelheim Int Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
HRP20181505T1 (hr) 2013-10-17 2018-11-02 Zealand Pharma A/S Acilirani analozi glukagona

Also Published As

Publication number Publication date
EP2585482A1 (fr) 2013-05-01
PH12012502472A1 (en) 2013-03-25
US20150376257A1 (en) 2015-12-31
ECSP12012357A (es) 2013-01-31
CA2802897A1 (fr) 2011-12-29
AU2011269430A1 (en) 2013-01-10
NZ604208A (en) 2014-10-31
EP2585482B1 (fr) 2019-03-27
MX2012014961A (es) 2013-02-26
PE20130338A1 (es) 2013-03-16
CN103068841A (zh) 2013-04-24
JP2013530969A (ja) 2013-08-01
BR112012033225A2 (pt) 2017-06-20
AP2013006671A0 (en) 2013-01-31
KR20130086343A (ko) 2013-08-01
CL2012003641A1 (es) 2013-09-06
TN2012000560A1 (en) 2014-04-01
CO6660483A2 (es) 2013-04-30
US20130157929A1 (en) 2013-06-20
US9169310B2 (en) 2015-10-27
WO2011160633A1 (fr) 2011-12-29
EA201291234A1 (ru) 2013-07-30
SG186764A1 (en) 2013-02-28
JP6023048B2 (ja) 2016-11-09

Similar Documents

Publication Publication Date Title
MA34383B1 (fr) Analogues de glucagon
MA33517B1 (fr) Analogues acylés du glucagon
MA32970B1 (fr) Analogues du glucagon
Bulycheva et al. Myelodysplasia is in the niche: novel concepts and emerging therapies
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
IL215027A (en) Anti-zb7r1 antibody, a formula containing it, and a method of increasing lymphocyte activity with its help
WO2006074428A3 (fr) Antagonistes de cxcr4 pour le traitement de troubles medicaux
CA2820681C (fr) Utilisation de lymphocytes t modifies par un recepteur chimerique d'antigenes chimerique pour traiter le cancer
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
MX2011006320A (es) Analogos de glucagon.
MX2011006314A (es) Analogos de glucagon.
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
NZ593813A (en) Glucagon analogues
EP2062917A3 (fr) Anticorps du récepteurs de l'érythropoïétine et leurs utilisations
MA34053B1 (fr) Polypeptides agonistes de liaison à dr5
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
WO2008097428A3 (fr) Composés et compositions tels que des modulateurs d'une activité gpr119
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
MA34640B1 (fr) Composition pharmaceutique, méthodes de traitement et ses utilisations
MY160892A (en) Antibodies to ccr2
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201200570A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119